Ovarian Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGynaecological CancersOvarian CancerSCE Medical Oncology

A 55-year-old woman with recurrent ovarian cancer is offered a clinical trial of mirvetuximab soravtansine. What biomarker must be positive for eligibility?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Folate receptor alpha (FRα) expression

Mirvetuximab soravtansine is an antibody-drug conjugate targeting folate receptor alpha (FRα), which is highly expressed in approximately 80% of high-grade serous ovarian cancers. The MIRASOL trial demonstrated OS benefit over chemotherapy in FRα-high, platinum-resistant ovarian cancer. FRα expression is assessed by IHC (PS2+ staining in ≥75% of viable tumour cells defines FRα-high). This represents the first biomarker-directed ADC therapy in ovarian cancer.

Reference: ESMO 2024 Ovarian Cancer Guidelines; MIRASOL Moore et al NEJM 2023